DataMEDS AI, Inc. (NASDAQ: MEDS) Stock Competitors & Peer Comparison
See MEDS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MEDS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDS | $1.74 | +93.31% | 2.4M | N/A | N/A | N/A |
| MCK | $896.55 | +1.71% | 106.6B | 22.31 | $40.82 | +0.39% |
| COR | $322.98 | +0.44% | 63.5B | 19.03 | $17.15 | +0.75% |
| CAH | $232.73 | -0.79% | 55B | 22.52 | $10.43 | +0.87% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $87.54 | -0.93% | 10.1B | 16.75 | $5.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| AHG | $0.80 | -4.09% | 696M | -3.82 | -$0.21 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| EMPG | $17.36 | +0.00% | 143M | 192.89 | $0.09 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
MEDS vs MCK Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, MCK has a market cap of 106.6B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while MCK trades at $896.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas MCK's P/E ratio is 22.31. In terms of profitability, MEDS's ROE is +8.78%, compared to MCK's ROE of -1.94%. Regarding short-term risk, MEDS is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
MEDS vs COR Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, COR has a market cap of 63.5B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while COR trades at $322.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas COR's P/E ratio is 19.03. In terms of profitability, MEDS's ROE is +8.78%, compared to COR's ROE of +1.06%. Regarding short-term risk, MEDS is more volatile compared to COR. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
MEDS vs CAH Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, CAH has a market cap of 55B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while CAH trades at $232.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas CAH's P/E ratio is 22.52. In terms of profitability, MEDS's ROE is +8.78%, compared to CAH's ROE of -0.60%. Regarding short-term risk, MEDS is more volatile compared to CAH. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
MEDS vs ABC Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas ABC's P/E ratio is 21.92. In terms of profitability, MEDS's ROE is +8.78%, compared to ABC's ROE of +1.06%. Regarding short-term risk, MEDS is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check ABC's competition here
Henry Schein, Inc. (NASDAQ: HSIC)
MEDS vs HSIC Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, HSIC has a market cap of 10.1B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while HSIC trades at $87.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas HSIC's P/E ratio is 16.75. In terms of profitability, MEDS's ROE is +8.78%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, MEDS is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check HSIC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
MEDS vs PDCO Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas PDCO's P/E ratio is 20.48. In terms of profitability, MEDS's ROE is +8.78%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, MEDS is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check PDCO's competition here
Akso Health Group (NASDAQ: AHG)
MEDS vs AHG Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, AHG has a market cap of 696M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while AHG trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas AHG's P/E ratio is -3.82. In terms of profitability, MEDS's ROE is +8.78%, compared to AHG's ROE of -0.50%. Regarding short-term risk, MEDS is more volatile compared to AHG. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check AHG's competition here
Owens & Minor, Inc. (NYSE: OMI)
MEDS vs OMI Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas OMI's P/E ratio is -0.47. In terms of profitability, MEDS's ROE is +8.78%, compared to OMI's ROE of +0.63%. Regarding short-term risk, MEDS is more volatile compared to OMI. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check OMI's competition here
Empro Group Inc. Ordinary shares (NASDAQ: EMPG)
MEDS vs EMPG Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while EMPG trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas EMPG's P/E ratio is 192.89. In terms of profitability, MEDS's ROE is +8.78%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, MEDS is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check EMPG's competition here
Accendra Health, Inc. (NYSE: ACH)
MEDS vs ACH Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, ACH has a market cap of 85.4M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while ACH trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas ACH's P/E ratio is 1.64. In terms of profitability, MEDS's ROE is +8.78%, compared to ACH's ROE of +0.63%. Regarding short-term risk, MEDS is more volatile compared to ACH. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check ACH's competition here
Akso Health Group (NASDAQ: HX)
MEDS vs HX Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas HX's P/E ratio is -1.84. In terms of profitability, MEDS's ROE is +8.78%, compared to HX's ROE of -1.07%. Regarding short-term risk, MEDS is more volatile compared to HX. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check HX's competition here
111, Inc. (NASDAQ: YI)
MEDS vs YI Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, YI has a market cap of 29.8M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while YI trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas YI's P/E ratio is -2.44. In terms of profitability, MEDS's ROE is +8.78%, compared to YI's ROE of +0.14%. Regarding short-term risk, MEDS is more volatile compared to YI. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
MEDS vs WGRX Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas WGRX's P/E ratio is -0.33. In terms of profitability, MEDS's ROE is +8.78%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, MEDS is more volatile compared to WGRX. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check WGRX's competition here
Zynex, Inc. (NASDAQ: ZYXI)
MEDS vs ZYXI Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, MEDS's ROE is +8.78%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, MEDS is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check ZYXI's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
MEDS vs HKPD Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, HKPD has a market cap of 1.4M. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while HKPD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas HKPD's P/E ratio is -2.08. In terms of profitability, MEDS's ROE is +8.78%, compared to HKPD's ROE of -0.15%. Regarding short-term risk, MEDS is more volatile compared to HKPD. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check HKPD's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
MEDS vs SNYR Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, SNYR has a market cap of 947K. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while SNYR trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas SNYR's P/E ratio is -0.06. In terms of profitability, MEDS's ROE is +8.78%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, MEDS is more volatile compared to SNYR. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
MEDS vs RDGT Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, RDGT has a market cap of 753.3K. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while RDGT trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas RDGT's P/E ratio is -0.02. In terms of profitability, MEDS's ROE is +8.78%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, MEDS is more volatile compared to RDGT. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
MEDS vs CVET Comparison September 2026
DataMEDS AI, Inc. (NASDAQ: MEDS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDS stands at 2.4M. In comparison, CVET has a market cap of 0. Regarding current trading prices, MEDS is priced at $1.74 on the NASDAQ, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDS currently has a P/E ratio of N/A, whereas CVET's P/E ratio is -69.97. In terms of profitability, MEDS's ROE is +8.78%, compared to CVET's ROE of -0.06%. Regarding short-term risk, MEDS is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for MEDS.Check CVET's competition here